Cavendish supported Oncimmune Holdings plc in their recent placing and conversion of debt into equity, raising £2.3 million to advance their pioneering work in autoantibody profiling and biomarker discovery, alongside €4m of debt conversion.

Geoff Nash, Corporate Finance Director at Cavendish, commented: “We are delighted to have assisted Oncimmune in securing this funding whilst substantially reducing their debt burden. This allows the new management team to further develop their ImmunoINSIGHTS™ platform and continue delivering valuable insights to the pharmaceutical and biotechnology industries.”

Oncimmune’s innovative approach to understanding the immune system is transforming the landscape of precision medicine. We look forward to witnessing their continued growth and success.